Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Sanofi : may seek U.S. approval for Dengvaxia despite Philippines outrage

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/08/2018 | 05:58pm CEST
FILE PHOTO:French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris

(This version of Mar.7's story corrects timeframe of filing decision in the United States in bullet point and paragraphs 10-11.)

PARIS (Reuters) - French pharmaceuticals group Sanofi says it will decide shortly whether to seek regulatory approval for dengue vaccine Dengvaxia in the United States, saying it was committed to the medicine despite a health scare in the Philippines.

David Loew, the head of Sanofi Pasteur, the group's vaccines division, said the company had complied with all regulations and had no regrets about the vaccine, Dengvaxia, was developed despite the Philippines suspending a vast government immunisation programme because of safety concerns.

"On the whole path of development, we always worked with the WHO and experts in the dengue community. We were always transparent," Loew told Reuters in an interview, referring to the World Health Organization and other regulators.

"You need to ask yourself: what was done with the information that was available at the time? Looking back, I would say no, we would not have done anything differently."

Loew said the company was contemplating the possibility of filing an application for the use of Dengvaxia in the United States and that a meeting with the Food and Drug Administration would take place within two months.

Any decision would be taken after the meeting, he said.

Some experts have argued Sanofi and regulators may have ignored warnings about how the vaccine was developed, but executives at Sanofi denied any errors.

Dengvaxia has been approved and registered in 19 countries, mostly in the developing world. It is currently under review by the European Medicines Agency.

(Reporting by Matthias Blamont; editing by Luke Baker)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
07:05pSANOFI : Galera raises $150 million, will hire staff for cancer-radiation side-e..
AQ
09/18SANOFI : unveils eczema drug data, as regulators mull label expansion
AQ
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/17SANOFI : Disclosure of trading in own shares
GL
09/17SANOFI : Positive Phase 3 results presented for Dupixent (dupilumab)
AQ
09/15SANOFI : Positive Phase 3 results presented for Dupixent® (dupilumab)
AQ
09/15SANOFI : Positive Phase 3 results presented for Dupixent® (dupilumab)
GL
09/14REGENERON PHARMACEUTICALS : FDA to Review Supplemental Biologics License Applica..
AQ
09/14SANOFI : creating China/emerging markets and primary care units
AQ
09/14SANOFI : swaps top execs with Bayer, triggering a reorganization that puts China..
AQ
More news
News from SeekingAlpha
09/15Regeneron and Sanofi's Dupixent shows treatment benefit in adolescents with a.. 
09/15STOCKS TO WATCH : Oracle Looks To Lift Tech Sector 
09/14Sanofi (SNY) Presents at Bank of America Merrill Lynch Global Healthcare Conf.. 
09/13Sanofi to refocus two global business units 
09/1236 'Safer' Dividend Healthcare WallStars For September 
STOCK PICK
At a crossroads
Financials (€)
Sales 2018 35 107 M
EBIT 2018 8 381 M
Net income 2018 5 005 M
Debt 2018 16 227 M
Yield 2018 4,10%
P/E ratio 2018 18,17
P/E ratio 2019 16,90
EV / Sales 2018 3,13x
EV / Sales 2019 3,02x
Capitalization 93 747 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 80,2 €
Spread / Average Target 7,1%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI4.25%109 911
JOHNSON & JOHNSON0.59%375 479
PFIZER18.75%252 129
NOVARTIS-1.14%215 800
ROCHE HOLDING LTD.-4.00%212 015
MERCK AND COMPANY25.15%187 284